Bausch + Lomb Corporation stock analysis
Bausch + Lomb Corporation (BLCO) Stock Price & Analysis
BLCO Stock Chart & Stats
- Day’s Range
- CAD 30.21 - CAD 30.46
- 52-Week Range
- CAD 20.25 - CAD 30.46
- Previous Close
- CAD 30.35
- Volume
- N/A
- Average Volume (3M)
- 2,922
- Market Cap
- CAD 10.89B
- Enterprise Value
- CAD 10.80B
- Total Cash (Recent Filing)
- CAD 513.00M
- Total Debt (Recent Filing)
- CAD 5.09B
- Price to Earnings (P/E)
- ―
- Beta
- 1.26
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- 0.52
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Diversified Eye Health Portfolio
The company operates across three complementary eye-health categories and multiple customer channels, reducing reliance on a single product or market. Repeat contact-lens purchases, procedure-driven consumables, and pharmaceutical and OTC demand provide several durable revenue streams.
Broad-Based Growth And Margin Expansion
Growth across all three operating segments indicates that recent performance is not dependent on one isolated business. Broad demand, combined with higher operating profitability, strengthens the company’s ability to reinvest in brands, innovation, and commercial execution.
Improving Cash Generation
The return to strong positive cash generation improves financial flexibility and supports investment in the product pipeline while also enabling debt reduction. If sustained, better cash conversion can strengthen the balance sheet and provide greater resilience through operating cycles.
Bears Say
Persistent Net Losses
Improved operating profitability has not yet translated into consistent bottom-line earnings. The continuing net loss indicates that costs, interest, or other non-operating pressures remain material, limiting shareholder returns and leaving profitability improvement unfinished.
Leverage Remains Above Target
Deleveraging is progressing, but leverage remains above management’s stated target and continues to require attention. Debt reduction may compete with acquisitions, innovation, or other capital uses, while sustained cash generation is needed to reach the desired balance-sheet position.
Interim CEO Transition
An interim leadership structure creates uncertainty around strategic continuity and long-term decision-making while the company advances its growth and pipeline plans. The transition may also keep management attention focused on succession and governance during an important execution period.
Bausch + Lomb Corporation News
BLCO FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
What is Bausch + Lomb Corporation’s market cap?
When is Bausch + Lomb Corporation’s upcoming earnings report date?
How were Bausch + Lomb Corporation’s earnings last quarter?
Is Bausch + Lomb Corporation overvalued?
Does Bausch + Lomb Corporation pay dividends?
What is Bausch + Lomb Corporation’s EPS estimate?
How many shares outstanding does Bausch + Lomb Corporation have?
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
What is the TipRanks Smart Score and how is it calculated?
Bausch + Lomb Corporation Stock Smart Score
Company Description
Bausch + Lomb Corporation
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Thomas J. Appio
- Employees
- 13,000
- Website
- www.bausch.com
- Address
- 520 Applewood Crescent, Vaughan, ON, L4K 4B4, CA
Bausch + Lomb Corporation (BLCO) Earnings & Revenues
BLCO Company Deck
BLCO Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with broad-based revenue growth, significant adjusted EBITDA and margin expansion, record quarterly cash generation, lower leverage, raised 2026 guidance, and continued momentum across key brands and pipeline programs. The main challenges were foreign-exchange headwinds, lower surgical equipment revenue tied to the placement strategy, slower international contact-lens growth, and the ongoing development and regulatory work required for pipeline programs.
View all TSE:BLCO earnings summariesBLCO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 6 |
| Technical Analysis | 3 | 1 | 6 |
| Moving Averages | 12 | 0 | 0 |
